National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
The present study was conducted on various clinical samples, in the Department of Microbiology, S.N medical college, Agra from February 2018 to July 2018. 72 Enterococcus isolates were identified. Maximum samples from which Enterococcus spp. was isolated is urine i.e. 39 (54.17%), followed by pus and blood i.e. 22 (30.55%) and 5 (6.94%) respectively. Maximum isolate is E. faecalis i.e. 62 (86.11%) followed by E.faecium i.e. 10 (13.89%). On Antimicrobial Susceptibility testing, Ampicillin, Ciprofloxacin, Levofloxacin, Tetracycline and Doxycycline show 70.83%, 38.88%, 30.55%, 58.33% and 52.77% resistance respectively. Among the 33 Enterococcal isolates tested by disc diffusion method, Erythromycin shows 57.57% resistance. Nitrofurantoin and Norfloxacin show 15.38% and 76.92% resistance respectively, among the 39 Enterococcal isolates obtained from urine. Vancomycin shows 4.16% resistance and High Level Gentamycin shows 18.05% resistance. The emergence of Vancomycin resistance and High Level Aminoglycoside resistance in Enterococci poses a serious threat to patient’s safety as it leaves fewer options for disease management. In the present study, Teicoplanin and Linezolid were found to be 100% susceptible for all the Enterococcal isolates, hence these drugs can be prescribed even for Vancomycin Resistant Enterococci (VRE).
Citations |
 |
 |
 |
 |
